Innate Pharma S.A. (NASDAQ:IPHA - Get Rating) - Stock analysts at SVB Leerink dropped their FY2026 earnings estimates for shares of Innate Pharma in a research report issued on Tuesday, May 10th. SVB Leerink analyst D. Graybosch now anticipates that the company will earn $0.58 per share for the year, down from their previous forecast of $0.75.
A number of other research firms have also recently commented on IPHA. HC Wainwright reiterated a "buy" rating and set a $11.50 price target on shares of Innate Pharma in a report on Friday, March 25th. Zacks Investment Research downgraded shares of Innate Pharma from a "hold" rating to a "sell" rating in a research report on Tuesday, May 3rd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, Innate Pharma presently has an average rating of "Buy" and a consensus price target of $9.90.
Shares of NASDAQ:IPHA traded down $0.03 during trading on Friday, reaching $2.79. 5,445 shares of the stock traded hands, compared to its average volume of 30,236. The stock has a 50-day moving average of $3.10 and a two-hundred day moving average of $4.06. Innate Pharma has a 52-week low of $2.66 and a 52-week high of $11.95. The company has a current ratio of 1.73, a quick ratio of 1.73 and a debt-to-equity ratio of 0.13.
A number of institutional investors have recently modified their holdings of IPHA. Balyasny Asset Management LLC bought a new position in Innate Pharma in the third quarter worth approximately $1,157,000. Two Sigma Securities LLC bought a new position in Innate Pharma in the third quarter worth approximately $106,000. Pura Vida Investments LLC bought a new position in Innate Pharma in the third quarter worth approximately $509,000. Affinity Asset Advisors LLC bought a new position in Innate Pharma in the third quarter worth approximately $771,000. Finally, Bank of America Corp DE raised its position in Innate Pharma by 41.9% in the fourth quarter. Bank of America Corp DE now owns 247,051 shares of the company's stock worth $1,127,000 after acquiring an additional 72,951 shares during the period. Institutional investors own 1.74% of the company's stock.
Innate Pharma Company Profile (Get Rating)
Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Innate Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.
While Innate Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here
